Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Starlite/ChEMBL | No references |
Homo sapiens | integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0062 | 0 | 0.5 | |
Wolbachia endosymbiont of Brugia malayi | phosphoribosylamine--glycine ligase | 0.0283 | 0.1816 | 1 |
Echinococcus granulosus | folate receptor beta | 0.0591 | 0.4352 | 1 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.014 | 0.0635 | 0.122 |
Echinococcus multilocularis | integrin alpha 3 | 0.0142 | 0.0651 | 0.1156 |
Loa Loa (eye worm) | tryptophan hydroxylase 1 | 0.0107 | 0.0363 | 0.0169 |
Loa Loa (eye worm) | integrin beta-2 | 0.0378 | 0.2599 | 1 |
Echinococcus multilocularis | tryptophan hydroxylase | 0.0107 | 0.0363 | 0.0467 |
Schistosoma mansoni | tyrosine/tryptophan monooxygenase | 0.0107 | 0.0363 | 0.0199 |
Leishmania major | phenylalanine-4-hydroxylase,phenylalanine-4-hydroxylase, putative | 0.0315 | 0.2083 | 0.5 |
Schistosoma mansoni | integrin alpha | 0.0185 | 0.1006 | 0.0853 |
Toxoplasma gondii | phenylalanine-4-hydroxylase | 0.0348 | 0.2353 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.0679 | 0.156 |
Mycobacterium ulcerans | phosphoribosylamine--glycine ligase | 0.0283 | 0.1816 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 0.0635 | 0.1368 |
Echinococcus granulosus | integrin beta 2 | 0.028 | 0.1792 | 0.3883 |
Schistosoma mansoni | tyrosine 3-monooxygenase | 0.0107 | 0.0363 | 0.0199 |
Mycobacterium leprae | PROBABLE PHOSPHORIBOSYLAMINE--GLYCINE LIGASE PURD (GARS) (GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE) (PHOSPHORIBOSYLGLYCINAMIDE SYNT | 0.0283 | 0.1816 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 0.0363 | 0.0169 |
Echinococcus multilocularis | integrin beta 2 | 0.028 | 0.1792 | 0.3883 |
Schistosoma mansoni | family A2 unassigned peptidase (A02 family) | 0.0232 | 0.1397 | 0.1251 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0285 | 0.1829 | 0.6614 |
Echinococcus granulosus | tryptophan hydroxylase | 0.0107 | 0.0363 | 0.0467 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0185 | 0.1006 | 0.2875 |
Schistosoma mansoni | integrin beta subunit | 0.0223 | 0.1319 | 0.1172 |
Brugia malayi | Integrin beta pat-3 precursor | 0.0378 | 0.2599 | 1 |
Toxoplasma gondii | aromatic amino acid hydrolase AAH2 | 0.0348 | 0.2353 | 1 |
Toxoplasma gondii | aromatic amino acid hydrolase AAH1 | 0.0315 | 0.2083 | 0.8383 |
Echinococcus granulosus | integrin alpha 3 | 0.0142 | 0.0651 | 0.1156 |
Echinococcus multilocularis | folate receptor beta | 0.0591 | 0.4352 | 1 |
Mycobacterium tuberculosis | Probable phosphoribosylformylglycinamidine CYCLO-ligase PurM (AIRS) (phosphoribosyl-aminoimidazole synthetase) (air synthase) | 0.0062 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.54 nM | Inhibition of fibrinogen binding to immobilized human glycoprotein alpha IIb beta3 integrin | ChEMBL. | No reference |
IC50 (binding) | = 0.54 nM | Inhibition of fibrinogen binding to immobilized human glycoprotein alpha IIb beta3 integrin | ChEMBL. | No reference |
IC50 (functional) | = 15 nM | Tested in vitro for the inhibition of ADP-induced aggregation of human blood platelets | ChEMBL. | No reference |
IC50 (functional) | = 15 nM | Tested in vitro for the inhibition of ADP-induced aggregation of human blood platelets | ChEMBL. | No reference |
Inhibition (functional) | = 65 % | Ex vivo platelet aggregation of compound was measured in guinea pig up to 5 hr after intraduodenal dose of 1 mg/kg | ChEMBL. | No reference |
Inhibition (functional) | = 75 % | Ex vivo platelet aggregation of compound was measured in guinea pig up to 5 hr after intraduodenal dose of 3 mg/kg | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.